The Association Between Alpha 1 Acid Glycoprotein Level and Outcome of Patients With Metastatic Cancer Treated With Docetaxel Based Chemotherapy
Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including
non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder
cancer.
One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein
Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated
with the outcome of docetaxel based therapy in non small cell lung cancer patients.
The investigators aim to prospectively study the association between the baseline plasma
level of alpha 1 acid glycoprotein (measured on the first day of the first cycle of
docetaxel) and the outcome (response rete, progression free survival, overall survival) of
docetaxel based therapy in patients with metastatic non small cell lung cancer, breast
cancer, stomach cancer, prostate cancer, and bladder cancer.
Observational
Observational Model: Cohort, Time Perspective: Prospective
The association between the baseline plasma level of alpha 1 acid glycoprotein and progression free survival of docetaxel based therapy in patients with metastatic cancer
The association between the baseline plasma level of alpha 1 acid glycoprotein and progression free survival of docetaxel based therapy in patients with metastatic non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer
3 years
No
Daniel Keizman, MD
Principal Investigator
Meir Medical Center
Israel: Ministry of Health
A1AGP1234
NCT01814150
April 2013
April 2018
Name | Location |
---|